Research Topics
| Prakash S MasanSummaryAffiliation: Duke University Medical Center Country: USA Publications
| Collaborators |
Detail Information
Publications
Atypical antipsychotics in the treatment of affective symptoms: a reviewPrakash S Masan
Department of Psychiatry, Duke University Medical Center, Durham, North Carolina 27702 3319, USA
Ann Clin Psychiatry 16:3-13. 2004....- Long-acting injectable antipsychotics in the elderly: guidelines for effective usePrakash S Masand
Program for Continuing Medical Education, Department of Psychiatry, Duke University Medical Center, Durham, North Carolina 27710, USA
Drugs Aging 20:1099-110. 2003..The choice of which drug to use should be based on patients' history of response and personal preference, clinician's previous experience and pharmacokinetic properties... - Tolerability and adherence issues in antidepressant therapyPrakash S Masand
Program for Continuing Medical Education, Duke University Medical Center, Durham, North Carolina 27710, USA
Clin Ther 25:2289-304. 2003.... - The safety of SSRIs in generalised anxiety disorder: any reason to be anxious?Prakash S Masand
Program for Continuing Medical Education, Department of Psychiatry, Box 3391, Duke University Medical Center, Durham, NC 27710, USA
Expert Opin Drug Saf 2:485-93. 2003..For both paroxetine and venlafaxine, the safety and tolerability profiles during treatment of GAD are consistent with those demonstrated during the short- and long-term treatment of patients with major depressive disorder... - Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapinePrakash S Masand
Department of Psychiatry, Duke University Medical Center, Durham, North Carolina 27710, USA
Ann Clin Psychiatry 14:175-82. 2002..It may be possible to prevent discontinuation symptoms with a cross taper to another antidepressant or by slowly tapering the antidepressant... - Does a preexisting anxiety disorder predict response to paroxetine in irritable bowel syndrome?Prakash S Masand
Department of Psychiatry, Duke University Medical Center, Durham, NC 27710, USA
Psychosomatics 43:451-5. 2002..Both groups had similar improvement in abdominal pain, constipation, diarrhea, incomplete emptying, and bloating/ abdominal distension. Paroxetine was very well tolerated... - Prescribing conventional antipsychotics in the era of novel antipsychotics: informed consent issuesPrakash S Masand
Duke University Medical Center, Department of Psychiatry, Durham, North Carolina, USA
Am J Ther 9:484-7. 2002..066, df = 2, Pearson chi(2) test). For patients who are receiving any antipsychotic therapy, discussions about the risks/benefits of treatments are integral for optimal treatment and medicolegal purposes... 
History of depressive and/or anxiety disorders as a predictor of treatment response: a post hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release in patients with fibromyalgiaChi Un Pae
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, North Carolina 27704, USA
Prog Neuropsychopharmacol Biol Psychiatry 33:996-1002. 2009..We investigated whether a history of depressive and/or anxiety disorders was associated with response to paroxetine controlled release (CR) in the treatment of fibromyalgia...- History of early abuse as a predictor of treatment response in patients with fibromyalgia: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled releaseChi Un Pae
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA
World J Biol Psychiatry 10:435-41. 2009.... - Methylphenidate extended release (OROS MPH) for the treatment of antidepressant-related sexual dysfunction in patients with treatment-resistant depression: results from a 4-week, double-blind, placebo-controlled trialChi Un Pae
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Duke Clinical Research Institute, Durham, NC 27705, USA
Clin Neuropharmacol 32:85-8. 2009..Adequately powered controlled trials are needed to fully evaluate the efficacy of OROS MPH in this area... - Transdermal selegiline: the new generation of monoamine oxidase inhibitorsAshwin A Patkar
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27704, USA
CNS Spectr 11:363-75. 2006..However, more research is needed. Clinicians should familiarize themselves with the properties and indications for the new generation of MAOIs... - Long-acting injectable naltrexone for the treatment of alcohol dependencePaolo Mannelli
Duke University Medical Center, 2218 Elder Street, Suite 123, Durham, NC 27705, USA
Expert Rev Neurother 7:1265-77. 2007..The clinical availability of extended-release naltrexone has the potential to enhance treatment outcomes for alcohol and other drug dependence disorders... - Clinical variables associated with early administration of antipsychotics in bipolar maniaChi Un Pae
Department of Psychiatry, Kangnam St Mary s Hospital, The Catholic University of Korea College of Medicine, 505 Banpo Dong, Seocho Gu, Seoul 137 701, Republic of Korea
Prog Neuropsychopharmacol Biol Psychiatry 30:151-4. 2006..0 and 13.1, respectively). This study suggests that some clinical factors in bipolar mania might be linked to the earlier antipsychotic treatment. However, more studies will be needed to confirm this finding... - A randomized, controlled, trial of controlled release paroxetine in fibromyalgiaAshwin A Patkar
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27704, USA
Am J Med 120:448-54. 2007..We investigated the efficacy and tolerability of paroxetine controlled release, a selective serotonin reuptake inhibitor in fibromyalgia... - Differential pharmacology of atypical antipsychotics: clinical implicationsPrakash S Masand
Duke University Medical Center, Durham, NC 27710, USA
Am J Health Syst Pharm 64:S3-8; quiz S24-5. 2007..Pharmacology of atypical antipsychotics and the clinical implications are reviewed... - A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depressionAshwin A Patkar
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27704, USA
J Clin Psychopharmacol 26:653-6. 2006..Combination of methylphenidate with antidepressants was well tolerated. Adequately powered, randomized, controlled trials are necessary to fully evaluate the efficacy of extended-release methylphenidate in TRD... - Paroxetine: safety and tolerability issuesDavid M Marks
Duke University Medical Center, Department of Psychiatry and Behavioural Sciences, 2218 Elder Street, Durham 27705, USA
Expert Opin Drug Saf 7:783-94. 2008.... - A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndromePrakash S Masand
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, 1001 Winstead Dr, Suite 200, Cary, NC 27513, USA
Psychosomatics 50:78-86. 2009..Irritable bowel syndrome (IBS) is a functional gastrointestinal (GI) disease that causes significant impairment in quality of life and accounts for $8 billion per year to the healthcare system and loss of productivity in the workplace... - Metabolic and endocrine disturbances in psychiatric disorders: a multidisciplinary approach to appropriate atypical antipsychotic utilizationPrakash S Masand
Department of Psychiatry, Duke University Medical Center, Durham, North Carolina, USA
CNS Spectr 10:suppl14 1-15. 2005.... - Pharmacotherapy of depression in pregnancyAshwin A Patkar
Department of Psychiatry, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
Ann Clin Psychiatry 16:87-100. 2004..We review the safety profiles of commonly used antidepressants, discuss clinical decision making based on risk-benefit considerations and make recommendations for pharmacological treatment of depressed women during pregnancy... - Comorbidity of irritable bowel syndrome in psychiatric patients: a reviewAmir Garakani
Department of Psychiatry, Mt. Sinai School of Medicine, New York, NY, USA
Am J Ther 10:61-7. 2003..Our article reviews the comorbidity of IBS in psychiatric patients and discusses implications for treatment... - Improving adherence to antipsychotic pharmacotherapyPrakash S Masand
Department of Psychiatry, Duke University Medical Center, Durham, North Carolina, USA
Curr Clin Pharmacol 1:47-56. 2006..To review the consequences of nonadherence to antipsychotic pharmacotherapy in patients with schizophrenia, as well as associated risk factors for nonadherence and methods of improving adherence... - Prevalence of irritable bowel syndrome in obsessive-compulsive disorderPrakash S Masand
Department of Psychiatry, Duke University Medical Center, Durham, NC 27705, USA
CNS Spectr 11:21-5. 2006..Irritable bowel syndrome (IBS) occurs more frequently in psychiatric patients, especially those with anxiety and mood disorders... - Management of fibromyalgiaAshwin A Patkar
Department of Psychiatry, Thomas Jefferson University, 833 Chestnut Street, Suite 210E, Philadelphia, PA 19107, USA
Curr Psychiatry Rep 5:218-24. 2003..Patience and positive attitude on part of the physician and active involvement of patients and their families in treatment are likely to enhance improvement... - The role of atypical antipsychotics in the treatment of deliriumThomas L Schwartz
Department of Psychiatry, S U N Y Upstate Medical University, Syracuse 13210, USA
Psychosomatics 43:171-4. 2002..g., schizophrenia or bipolar disorder), but few studies have evaluated them in the treatment of delirium. This paper reviews the pertinent literature and summarizes tentative guidelines for novel antipsychotic use in delirium... - Second-generation antipsychotics and the metabolic syndromePrakash S Masand
Duke University Medical Center, 110 Swift Avenue, Suite 1, Durham, NC 27705, USA
Curr Psychiatry Rep 7:153-4. 2005 
The impact of the CONSORT statement on reporting of randomized clinical trials in psychiatryChangsu Han
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center and Duke Clinical Research Institute, Durham, NC, USA
Contemp Clin Trials 30:116-22. 2009..Although the overall quality of reporting on psychiatric RCTs generally improved after publication of the CONSORT statement, reporting the details of randomization, blinding, and obtaining informed consent remain insufficient...- Weight decline in patients switching from olanzapine to quetiapineSanjay Gupta
Department of Psychiatry, University of Buffalo, School of Medicine and Biomedical Sciences, Buffalo, NY, USA
Schizophr Res 70:57-62. 2004..Prospective controlled trials of longer duration and larger number of subjects are needed... - Use of atypical antipsychotics in a Veterans Affairs hospitalThomas L Schwartz
Department of Psychiatry, SUNY Upstate Medical University, New York, USA
Prog Neuropsychopharmacol Biol Psychiatry 26:1207-10. 2002.... - Safety considerations in pharmacotherapy of bipolar disorderPrakash S Masand
Department of Psychiatry, Duke University Medical Center, 110 Swift Ave, Suite 1, Durham, NC 27705, USA
CNS Spectr 9:16-26. 2004..More research is needed to understand potential risks of various drugs and to devise and incorporate monitoring protocols in the treatment regimen...